Immutopics, Inc. was acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016. Quidel is excited to have Immutopics join the Quidel family and portfolio of products and believes the combination of the Immutopics portfolio with Quidel's MicroVueTM products will enhance our ability to serve the bone health research community. Please see About Us for additional information.


Human FGF-23 (C-Terminal) ELISA kit

For the Determination of Human Fibroblast Growth Factor-23 Levels in Plasma or Cell Culture Media.
Description Item # (µL) Incubation Time Sensitivity Type
ELISA kit 60-6100 100 3 hour + 30 min 1.5 RU/mL 96 well microplate
(2nd Generation)